ARCHIVES

Phase II Study Finds Dasatinib May Overcome ALL Resistance

This article is from The Cancer Letter archive.

Vol. 30 No. 5 | May 25, 2007

Download PDF Visit The Full Archive

Related Articles

DCE Board Ok’s New RFA Programs worth $14 Million

June 29, 1990

Rituximab Prolonged Survival Of CLL In Phase III Study

September 24, 2010

Cancer Letter Takes Two Weeks Off

August 28, 1987

Peter Boyle Elected IARC Director

May 23, 2003

Officials: Poisoning Unrelated to MD Anderson; Critics Allege Dysfunction in Handling of Affair

September 19, 2014

In Brief: Long Island In, Seattle Out Of Community Based Cancer Program; Six Still In Running

December 10, 1976